Ehsan Parvaresh Rizi

Ehsan Parvaresh Rizi

Auto-generated profile, based on publicly available information

Ehsan Parvaresh Rizi

Late-Stage Development, Cardiovascular, Renal, and Metabolism, Biopharmaceutical Research and Development, AstraZeneca, Mölndal, Sweden

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
EREhsan Parvaresh Rizi
Ehsan Parvaresh Rizi
YTYvonne Teo
Yvonne Teo
Melvin Khee-Shing LeowMelvin Khee-Shing Leow
Melvin Khee-Shing Leow
EKEric Yin Hao Khoo
Eric Yin Hao Khoo
CYChia Rou Yeo
Chia Rou Yeo
CKChin Meng Khoo
Chin Meng Khoo
Among Asian ethnic groups, Chinese or Malays are more insulin sensitive than South- Asians, in particular in lean individuals.Wehave further reported that body fat partitioning did not explain this ethnic difference in insulin sensitivity. We examined whether adipocytokines might explain the ethnic differences in the relationship between obesity and insulin resistance among the three major ethnic groups in Singapore. This was a cross-sectional study. We studied 101 Chinese, 82 Malays, and 81 South-Asian men. Insulin sensitivity index (ISI) was measured using hyperinsulinemic euglycemic clamp. Visceral (VAT) and subcutaneous (SAT) adipose tissue volumes were quantified using magnetic resonance imaging. Plasma total and high-molecular-weight adiponectin, leptin, visfatin, apelin, interleukin-6 (IL-6), fibroblast growth factor 21 (FGF21), retinol binding protein-4 (RBP-4) and resistin were measured using enzyme linked immunoassays. Principle component analysis on the adipocytokines identified 3 principal components (PCs) which explained 49.5% of the total variance. Adiponectin loaded negatively, and leptin and FGF21 loaded positively onto PC1. Visfatin, resistin and apelin all loaded positively onto PC2. IL-6 loaded positively and RBP-4 negatively onto PC3. Only PC1 was negatively associated with ISI in all ethnic groups. In the path analysis, SAT and VAT were negatively associated with ISI in Chinese and Malays without significant mediatory role of PC1. In South-Asians, the relationship between VAT and ISI was mediated partly through PC1, whereas the relationship between SAT and ISI was mediated mainly through PC1. The relationships between abdominal obesity, adipocytokines and insulin sensitivity differ between ethnic groups. Adiponectin, leptin and FGF21 play a mediating role in the relationship between abdominal adiposity and insulin resistance in South-Asians, but not in Malays or Chinese.

12 January 2026 in JMIR Preprints
Verified
Preprint
Open access
ANAndrzej Nowojewski
Andrzej Nowojewski
OEOlga Elizarova
Olga Elizarova
ARAnnika Rutgersson
Annika Rutgersson
AZAnna Zarodkiewicz
Anna Zarodkiewicz
YJYunyun Jiang
Yunyun Jiang
RSRobert F. Storey
Robert F. Storey
BACKGROUND Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. OBJECTIVE This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. METHODS DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. RESULTS In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. CONCLUSIONS This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models. CLINICALTRIAL

21 September 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ANAndrzej Nowojewski
Andrzej Nowojewski
OEOlga Elizarova
Olga Elizarova
ARAnnika Rutgersson
Annika Rutgersson
AZAnna Zarodkiewicz
Anna Zarodkiewicz
YJYunyun Jiang
Yunyun Jiang
RSRobert F. Storey
Robert F. Storey
Background: Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. Objective: This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. Methods: DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. Results: In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. Conclusions: This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models.